Hims & Hers Health, Inc. (NYSE:HIMS) Insider Sells $47,377.15 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 2,335 shares of the stock in a transaction dated Tuesday, July 23rd. The shares were sold at an average price of $20.29, for a total transaction of $47,377.15. Following the transaction, the insider now directly owns 166,809 shares of the company’s stock, valued at approximately $3,384,554.61. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Soleil Boughton also recently made the following trade(s):

• On Tuesday, July 9th, Soleil Boughton sold 2,335 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.28, for a total transaction of $47,353.80.
• On Thursday, May 30th, Soleil Boughton sold 129,667 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.55, for a total transaction of $2,664,656.85.
• On Tuesday, May 28th, Soleil Boughton sold 2,502 shares of Hims & Hers Health stock. The shares were sold at an average price of $17.33, for a total transaction of $43,359.66.
• On Monday, May 20th, Soleil Boughton sold 4,915 shares of Hims & Hers Health stock. The shares were sold at an average price of $20.01, for a total transaction of $98,349.15.
• On Monday, May 13th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.33, for a total transaction of $30,861.99.
• On Monday, April 29th, Soleil Boughton sold 2,503 shares of Hims & Hers Health stock. The shares were sold at an average price of $12.56, for a total transaction of $31,437.68.

Hims & Hers Health Price Performance

Shares of NYSE:HIMS opened at $21.77 on Friday. The firm has a 50 day moving average of $21.07 and a 200 day moving average of $15.28. Hims & Hers Health, Inc. has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings results on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.02 by $0.03. Hims & Hers Health had a negative net margin of 0.24% and a negative return on equity of 0.70%. The business had revenue of $278.20 million for the quarter, compared to analyst estimates of $270.37 million. During the same period in the previous year, the company earned ($0.05) earnings per share. The business’s revenue for the quarter was up 45.8% on a year-over-year basis. Equities research analysts predict that Hims & Hers Health, Inc. will post 0.2 EPS for the current year.

Wall Street Analyst Weigh In

HIMS has been the topic of several recent research reports. Bank of America upped their target price on shares of Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research report on Thursday, June 13th. Canaccord Genuity Group initiated coverage on shares of Hims & Hers Health in a research report on Wednesday, April 10th. They set a “buy” rating and a $20.00 target price on the stock. Truist Financial upped their target price on shares of Hims & Hers Health from $13.00 to $23.00 and gave the company a “hold” rating in a research report on Thursday, July 18th. TD Cowen increased their price objective on shares of Hims & Hers Health from $15.00 to $25.00 and gave the stock a “buy” rating in a research report on Thursday, July 11th. Finally, Seaport Res Ptn reissued a “buy” rating on shares of Hims & Hers Health in a research report on Friday, April 26th. Seven equities research analysts have rated the stock with a hold rating and nine have issued a buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $19.07.

Institutional Investors Weigh In On Hims & Hers Health

Large investors have recently made changes to their positions in the stock. Nisa Investment Advisors LLC grew its holdings in shares of Hims & Hers Health by 679.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,839 shares of the company’s stock valued at $37,000 after buying an additional 1,603 shares during the last quarter. Certuity LLC acquired a new position in Hims & Hers Health during the fourth quarter valued at $109,000. Belpointe Asset Management LLC lifted its position in Hims & Hers Health by 10.0% during the fourth quarter. Belpointe Asset Management LLC now owns 13,238 shares of the company’s stock valued at $118,000 after purchasing an additional 1,205 shares during the period. Custom Index Systems LLC acquired a new position in Hims & Hers Health during the fourth quarter valued at $132,000. Finally, B. Riley Wealth Advisors Inc. acquired a new position in Hims & Hers Health during the fourth quarter valued at $155,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

About Hims & Hers Health

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.